Catalyst Pharmaceutical
CPRX
CPRX was delisted on the 14th of July, 2026.
52 hedge funds and large institutions have $78.7M invested in Catalyst Pharmaceutical in 2014 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 12 increasing their positions, 10 reducing their positions, and 13 closing their positions.
135% more call options, than puts
Call options by funds: $1.54M | Put options by funds: $656K
39% more capital invested
Capital invested by funds: $56.4M → $78.7M (+$22.3M)
38% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 13
20% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 10
11% more funds holding
Funds holding: 47 → 52 (+5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$11.7M |
| 2 |
Morgan Stanley
New York
|
+$3.23M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.79M |
| 4 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$599K |
| 5 |
Renaissance Technologies
New York
|
+$514K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$4.79M |
| 2 |
PA
Perceptive Advisors
New York
|
-$3.79M |
| 3 |
BC
Broadfin Capital
New York
|
-$2.61M |
| 4 |
SC
Sophrosyne Capital
New York
|
-$1.52M |
| 5 |
GTC
Ghost Tree Capital
New York
|
-$1.14M |
CPRX Hedge Fund Activity: Q3 2014 in Review
52 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q3 2014, worth a combined $78.7M — up 39% from $56.4M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new CPRX positions and 13 closed out — a net gain of 5 holders — while 12 added to existing stakes and 10 trimmed.
The largest buyer was Baker Bros. Advisors, adding an estimated $11.7M. The largest seller was OrbiMed, exiting entirely with an estimated $4.79M sold.
- 52 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q3 2014, up from 47 in Q2 2014.
- Funds reported $78.7M of Catalyst Pharmaceutical stock for Q3 2014, up 39% quarter-over-quarter.
- 18 funds opened new Catalyst Pharmaceutical positions in Q3 2014 and 13 closed out, a net change of +5 holders.
- The largest Catalyst Pharmaceutical buyer in Q3 2014 was Baker Bros. Advisors, an estimated $11.7M added.
- The largest Catalyst Pharmaceutical seller in Q3 2014 was OrbiMed, an estimated $4.79M sold.
Based on aggregated 13F filings for Q3 2014.